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Abstract  
 
Introduction: 
The clinical outcome of patients with squamous cell carcinoma (SCC) located in the head and 
neck has remained poor despite ongoing advances in diagnosis and management. Interleukin-
6(IL-6) is a multi-functional cytokine that plays an important role in the process of cell 
differentiation and is increased in several malignancies. The aim of this study was to 
investigate the serum levels of interleukin-6 in patients with oral tongue SCC. 
 
Materials and Methods:  
In a cross-sectional study, 17 patients with oral tongue SCC were compared with the same 
number of age- and gender-matched healthy subjects. Serum IL-6 level fluctuation was 
determined using an immunological technique, before detecting its possible association with 
the subjects’ age, gender, drinking and smoking history, cancer site, and disease severity. 
 
Results:  
The intensity of serum IL-6 in patients with oral tongue SCC was statistically significantly 
higher than that in healthy subjects (P<0.001). Serum IL-6 level was independent of the 
patients’ age, gender, smoking and drinking history as well as cancer stage.  
 
Conclusion:   
IL-6 is a valuable biomarker in the diagnosis of oral tongue SCC. Its high sensitivity makes 
prediction of this condition possible, while this biomarker can also be used to screen high-risk 
patients. 
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Introduction  
Cancer of the oral cavity is the sixth most 
frequently observed type of cancer in the 
world, and more than 90% of reported oral 
cancers are squamous cell carcinomas 
(SCC) (1). Oral tongue SCC (OTSCC) is the 
most common cancer diagnosed in the oral 
cavity, accounting for 20–40% of oral 
carcinomas (2). Despite advances in surgery, 
radiation and chemotherapy, the oral cancer 
5-year survival rate has not significantly 
improved over recent years, and remains at 
approximately 50–55% (1). In fact, despite 
improvements in locoregional control, 
morbidity and mortality rates in these 
cancers have not significantly improved over 
the past three decades (1,3).  
The mortality rate in oral SCC can be 
effectively controlled through efforts 
towards early diagnosis and prevention (3). 
SCC of the head and neck is usually 
diagnosed in the absence of specific 
symptoms, which in many cases may delay 
diagnosis. Therefore, availability of sensitive 
and specific biomarkers to achieve early 
diagnosis would be highly beneficial (4). 
Interleukin-6 (IL-6) is a multi-functional 
cytokine that plays an important role in 
differentiation and growth factors for a 
variety of cells such as B-cells, T-cells, 
neuronal cells, osteoclasts, and endothelial 
cells (5). Several human tumor cells, 
including esophageal SCC, multiple 
myeloma and lung carcinoma, have been 
reported to produce IL-6 (6). Thus, the aim 
of this study was to evaluate the secretion 
level of IL-6 in OTSCC and to investigate its 
possible association with severity and risk 
factors. 
 
Materials and Methods 
Seventeen patients with OTSCC in the 
North-West of Iran referred to the 
Otolaryngology Clinic at Imam Reza 
Hospital (Tabriz University of Medical 
Science) were enrolled in this study. 
Seventeen healthy age- and gender-
matched individuals were selected as a 
control group. Exclusion criteria included a 
history of recent traumas, acute infections, 
recent burns, lacerations, previous surgery, 
chemotherapy or radiotherapy. All patients 
were recently diagnosed with a primary 
OTSCC.  Control variables were age, sex, 
smoking history, the cancer site and stage. 
In the control group, no subjects had a 
record of recent trauma, laceration, 
infection, illness, previous surgery, 
smoking or drinking problems. Control 
subjects underwent a physical examination 
before selection.  
A 3-ml blood sample was taken from every 
subject prior to surgery. The centrifuged 
blood samples were stored at −70 °C before 
testing. The intensity of serum IL-6 was 
determined by using a quantitative sandwich 
enzyme-linked immunosorbent assay 
(ELISA) technique (eBioscience- Platinum 
ELISA-MedSystems Gmbh, Vienna, 
Austria). The data were tabulated using 
SPSS 17 (Polar Engineering and Consulting) 
for statistical analysis. P<0.05 was set as the 
critical level of significance. Descriptive 
data are presented as percentiles, while a 
Chi-square test was conducted to analyze 
qualitative data. The qualitative data 
obtained from the small number of subjects 
were analyzed after running a non-
parametric Mann Whitney U-test. To 
estimate the correlation index between IL-6 
range and age, a Kendall test of correlation 
was performed, while the sensitivity level of 
IL-6 was tested using receiver operating 
characteristic (ROC). Similarly, P<0.05 was 
set as the critical level of significance.  
 
Results  
Seventeen patients were enrolled with 
OTSCC and 17 age- and gender-matched 
healthy controls were enrolled in this study. 
There were eight males and nine females in 
both groups. The mean age of the patients 
was 64.2±14.02 years, compared with 62. 
17±14.23 years in the control group(Fig.1). 
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Fig 1: Average age in the treatment and control 
groups 
 
The average serum IL-6 level in patients 
with oral cavity SCC was 5.8 pg/ml 
compared with the much lower value of 
0.2 pg/ml in the control group (P<0.001) 
(Fig.2). 
 
Fig2: Intensity of serum IL-6 levels in treatment 
and control groups 
One patient had a smoking history, 
involving use of around 25±12.9 packs per 
year. The average serum IL-6 level among 
non-smokers was 11.5±0.0 pg/ml compared 
with 6.13±7.16 pg/ml in this patient 
(P<0.05).  
Stage of cancer progression at the time of 
the study did not seem to affect intensity 
of serum IL-6 levels (8.1±1.3pg/ml, 
4.21±2.85 pg/ml, and 7.25±3.35 pg/ml for 
Stage 1 (n=3), Stage 2 (n=8) and Stage 3 
(n=6), respectively; P<0.67). Similarly, 
elevated serum IL-6 level was not 
associated with patients’ gender (P<0.58), 
age (P<0.08) or positive/negative lymph 
nodes (P<0.757). As none of the patients 
had a history of drinking alcoholic 
beverages, any possible connection 
between this risk factor and serum IL-6 
level was undetectable. Statistical details 
are summarized in Table 1. 
Table 1: Research findings 
Variable 
Mean serum  
IL-6 (pg/ml) 
P-value 
Sex 
Male  7.5±10.65 
0.58 
Female  5.47±3.2 
TNM Stage 
Stage 1  8.1±1.3 
0.67 Stage 2  4.21±2.85 
Stage 3  7.25±3.35 
Lymph node involvement 
Positive  6.01±9.1 
0.757 
Negative  7.25±3.35 
Addiction 
Smoker  6.13±7.16 
0.5 
Non-smoker  11.5±0.0 
 
In patients affected with OTSCC, the 
serum IL-6 sensitivity was high, at close to 
95% (Fig.3). 
 
Fig 3: Sensitivity of IL-6 in oral tongue squamous 
cell carcinoma patients 
 
Discussion  
Head and neck SCC is reported to 
threaten the lives of 50,000 people in the 
United States each year; 13,000 of whom 
do not survive (7). Advances in surgical 
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and non-surgical techniques have been 
successful in controlling this cancer, 
although they have not affected rates of 
mortality or relapse. Recently, the 
development of histological markers and 
inflammatory mediators that enable us to 
detect the potential for progression and 
aggressive growth have become very 
popular (7,6). Numerous studies support 
the fact that multiple biomarkers are 
released in head and neck carcinomas (8). 
Inflammatory conditions in the oral cavity 
increase cytokine production, leading to 
raised serum levels of IL-1, 6, 8 and tumor 
necrosis factor-alpha (TNF-α). Increased 
serum levels of these markers provides the 
potential for their use in the prediction and 
treatment of head and neck SCC (9,10). 
In particular, IL-6 and IL-8 are important 
factors in predicting cell differentiation 
and growth of tumor cells. Their 
measurable increase in renal cell 
carcinoma, OSCC and lymphoma has been 
reported (6,11).   
In one study, salivary levels of IL-1α, IL-
6, IL-8, vascular endothelial growth factor 
A (VEGF-a) and TNF-α were able to 
predict the progression of tongue SCC 
from high-risk to neoplasm, serving as 
potential biomarkers for cancer screening 
and early detection (12). 
In a study by Rhodus et al., an elevated 
saliva intensity of TNF-a, and IL-1, 6, 8, in 
oral cavity SCC was detected. In this 
study, it was shown that in moderate and 
severe Lichen planus dysplasia, the saliva 
intensity of TNF-α, IL-1, 6, 8 was much 
higher than that in healthy individuals 
(13). The authors argue that while the 
intensity of TNF-α and IL-1 increased to 
levels similar to those detected in oral 
SCC, the levels of IL-6 and IL-8 remained 
lower in intensity than those seen in oral 
SCC. This finding indicates that IL-6 and 
IL-8 may be remarkable factors in oral 
cavity SCC. This finding was supported in 
a study by Saheb Jame et al. who 
examined a very high saliva intensity of 
IL-6 up to 15.9 pg/ml in oral SCC (14). 
This is contrary to the slow and 
insignificant secretion of IL1, 8 and TNF-
α in the patients’ blood.  
The current study greatly supports the 
increase of IL-6 in oral cavity SCC. 
Moreover, the serum level of IL-6 showed 
a high diagnostic sensitivity of nearly 95% 
in patients with oral cavity SCC. 
This finding was more in line with those 
of Duffy et al. and Hamad et al. who 
measured a sensitivity of 80% in the 
patients’ serum and 73% in their saliva. 
They acknowledged IL-6 as a determining 
biomarker in oral cavity SCC (15). Unlike 
Saheb Jame et al., Hamad et al. reported a 
higher increase of serum IL-8 sensitivity, 
close to 90%, in oral cavity SCC (16).  
Despite the controversies, IL-6 is 
suggested as a biomarker for early 
diagnosis and follow-up to detect relapse 
in oral cavity carcinomas (16). Since 
patients are commonly diagnosed with oral 
cavity carcinoma at the later stages of the 
disease, it is expected that serum IL-6 
levels increase with cancer stage. The 
increasing inflammation and lesion region 
would increase the serum IL-6 level. 
Masaaki et al. reported the remarkably 
high serum IL-6 levels in invasive tumors 
(17). In their study, a strong connection 
existed between serum IL-6 levels and 
excessive weight loss, invasiveness of the 
tumor to surrounding tissues, lymph node 
involvement, and impossibility of 
complete tumor resection. Similar findings 
were reported by Riedel et al. between the 
average serum IL-6 level and the cancer 
stage (6). In other cases with lymph node 
involvement, a higher serum IL-6 was also 
observed.  
Contrary to the previous studies, the 
current researchers could not detect any 
association between serum IL-6 levels and 
cancer stage in OTSCC. A probable reason 
was the small number of patients in this 
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study that precluded any general 
statements. Moreover, the researchers in 
this study found no connections between 
their patients’ gender or age and serum IL-
6 sensitivity levels. This reinforces the 
reliability of serum IL-6 as an independent 
biomarker in patients diagnosed with 
OTSCC. Similar findings by St. John et al. 
supported the lack of connection between 
gender, age or drinking and smoking 
history in the patients and their serum IL-6 
levels. In conclusion, among biomarkers 
such as saliva level, serum IL-6 has a 
higher diagnostic significance in OCSCC.  
 
Conclusion 
Interleukin-6 is a valuable biomarker for 
the diagnosis of head and neck SCCs. It 
has a high sensitivity in predicting these 
patients and is recommended for use in 
screening high-risk cases.  
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